Format

Send to

Choose Destination
Clin Cancer Res. 2014 Sep 15;20(18):4827-36. doi: 10.1158/1078-0432.CCR-14-0603. Epub 2014 Jul 1.

Personalized medicine for patients with advanced cancer in the phase I program at MD Anderson: validation and landmark analyses.

Author information

1
Department of Investigational Cancer Therapeutics, Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, Texas. atsimber@mdanderson.org.
2
Department of Biostatistics, West Virginia University Health Science Center, Morgantown, West Virginia.
3
Department of Investigational Cancer Therapeutics, Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, Texas.
4
Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
5
Department of Internal Medicine, Moores Cancer Center-University of California San Diego, LaJolla, California.
6
Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Abstract

PURPOSE:

The purpose of this study was to confirm our previous results that targeted agents matched with tumor molecular alterations were associated with improved outcomes compared with nonmatched therapy in patients with advanced cancer.

EXPERIMENTAL DESIGN:

Outcomes of patients who were referred for treatment on phase I clinical trials at The University of Texas MD Anderson Cancer Center (Houston, TX) from March 2011 to January 2012 were compared between those who had received targeted therapy and those for whom no targeted therapy was available. Two-month landmark analyses for overall and progression-free survival (PFS) combining previously published and validation cohort patient data were performed.

RESULTS:

In patients with one alteration, matched therapy (n = 143) compared with treatment without matching (n = 236) was associated with a higher objective response rate (12% vs. 5%; P < 0.0001), longer PFS (median, 3.9 vs. 2.2 months; P = 0.001), and longer survival (median, 11.4 vs. 8.6 months; P = 0.04). In multivariate analysis, matched therapy was an independent factor predicting response (P < 0.015) and PFS (P < 0.004). Two-month landmark analyses in the matched therapy group demonstrated that the median survival of responders was 30.5 months compared with 11.3 months for nonresponders (P = 0.01); and the median PFS was 38.7 months compared with 5.9 months, respectively (P < 0.0001). The respective values in the nonmatched therapy group were 9.8 and 9.4 months (P = 0.46) and 8.5 and 4.2 months (P = 0.18).

CONCLUSION:

This validation analysis confirms our previous observations. In the matched therapy group, 2-month landmark analyses demonstrated that responders have longer survival and PFS than nonresponders.

PMID:
24987059
PMCID:
PMC4518867
DOI:
10.1158/1078-0432.CCR-14-0603
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center